Advanced Prostate Cancer VL

New Concepts in Androgen Deprivation Therapy (ADT) Agonists vs. Antagonists and All the Rest- Tom Keane

Details
Thomas Keane's video lecture is a state of the art review of personalized androgen deprivation therapy (ADT) for men being treated for advanced prostate cancer. This discussion includes the most recent data and considerations relative to identifying patients with cardiovascular disease, obesity and testosterone, fatty acid synthase (FSH) and adipogenous, high volume metastatic disease, use of doce...

Next-generation sequencing of prostate tumors: Use of individualised biomarkers for prognosis and treatment- Martin Spahn

Details
Next-generation sequencing of prostate tumors: Use of individualised biomarkers for prognosis and treatment (STOP 6) Biography: Martin Spahn, MD

Laurence Klotz on Active surveillance or: Shrinking the gray zone - STOP 6

Details
Active surveillance or Shrinking the gray zone (STOP 6) Biography: Laurence Klotz, MD

Karim Fizazi on Sequencing: Combination or individualized treatment - STOP 6

Details
Sequencing: Combination or individualized treatment (STOP 6) Biography: Karim Fizazi, MD

Karim Fizazi v. Bertrand Tombal on 'Hormone-naive metastatic prostate cancer patients should get chemotherapy and ADT as a standard of care' versus 'ADT and AR pathway-targeted agents still have a rol...

Details
Karim Fizazi and Bertrand Tombal discuss 'Hormone-naive metastatic prostate cancer patients should get chemotherapy and ADT as a standard of care' versus 'ADT and AR pathway-targeted agents still have a role in these patients’. Biographies: Karim Fizazi, MD Bertrand Tombal, MD, Ph.D. , us professor and Chairman, Service d'Urologie, Cliniques Universitaires Saint Luc, Université Catholique de Louva...

Mark Emberton on Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care - STOP 6

Details
Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care (STOP 6) Biography: Mark Emberton, MD, FRCS is a Professor of Interventional Oncology at the University College London. He is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of The Charity Prostate Cancer UK. Dr. Emberton was appoi...

Journal Club: Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormones Agonist and an Antagonist

Details
Thomas Keane provides a journal club review on the article, "Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormones Agonist and an Antagonist", published in the European Association of Urology. The hypothesis and approach for this article includes a discussion around if a GnRH antagonist produce the same risk of cardiovascular complication when compared to an LHRH agonist. Also,...

Journal Club Review: Pharmacokinetic Aspects of the Two Novel Oral Drugs - Charles Ryan

Details
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide Guillemette E. Benoist, Rianne J. Hendricks, Peter F. A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger, Nielka P. van Erp In this Journal Club presentation, Dr. Charles Ryan's key points include h...

Role of the Gonadotrophin-Releasing Hormone Antagonists and Advanced Hormone-Dependent Prostate Cancer - Journal review

Details
This edition of Keane’s Corner is a Journal Club discussion on the article, “The Role of the Gonadotrophin-Releasing Hormone Antagonists in the Treatment of Patients with Advanced Hormone-Dependent Prostate Cancer in the UK”, published in the World Journal of Urology. Authors: Derek J. Rosario, Patrick Davey, James Green, Damien Greene, Bruce Turner, Heather Payne and Mike Kirby An overview of the...

Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer - Matthew Roe

Details
UroToday is excited to host a lecture from a leading cardiologist’s perspective, Dr. Matthew Roe from the Duke Clinical Research Institute. Dr. Roe’s discussion features the topics: atherosclerotic plaque formation and plaque instability and incidences of prostate cancer and cardiovascular events. In addition, cardiovascular risks with androgen deprivation therapy, GnRH antagonists and GnRH agonis...